Compare · APR vs DXCM
APR vs DXCM
Side-by-side comparison of Apria Inc. (APR) and DexCom Inc. (DXCM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both APR and DXCM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $27.61B, about 20.9x APR ($1.32B).
- DXCM has hit the wire 6 times in the past 4 weeks while APR has been quiet.
- DXCM has more recent analyst coverage (25 ratings vs 6 for APR).
- Company
- Apria Inc.
- DexCom Inc.
- Price
- $37.49-0.01%
- $71.54+1.52%
- Market cap
- $1.32B
- $27.61B
- 1M return
- -
- +2.57%
- 1Y return
- -
- -20.08%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2005
- News (4w)
- 0
- 6
- Recent ratings
- 6
- 25
Apria Inc.
Apria, Inc. provides integrated home healthcare equipment and related services in the United States. The company offers home respiratory therapies, including the supply of stationary and portable home oxygen equipment, and non-invasive ventilators; obstructive sleep apnea therapy devices comprising continuous positive airway pressure and bi-level positive airway pressure devices, and patient support services; and negative pressure wound therapy products. It also provides a range of home medical equipment and other products, and services for patients with home care needs; and clinical and administrative support services, and related products and supplies to patients. The company was incorporated in 2018 and is headquartered in Indianapolis, Indiana.
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest APR
- SEC Form SC 13G/A filed by Apria Inc. (Amendment)
- SEC Form 15-12B filed by Apria Inc.
- Executives Sell Over $640M Of 5 Stocks
- SEC Form 4: Walker Robert P. returned $192,450 worth of shares to the company (5,132 units at $37.50), closing all direct ownership in the company (tax liability)
- SEC Form 4: Apria Holdings Llc sold $532,031,812 worth of shares (14,187,515 units at $37.50)
- SEC Form 4 filed by Snyder Lynn Shapiro to satisfy withholding obligation
- SEC Form 4: Scally Celina M. returned $166,425 worth of shares to the company (4,438 units at $37.50), closing all direct ownership in the company (tax withholding)
- SEC Form 4 filed by Lee Christopher G (withholding tax)
- SEC Form 4: Morris Debra L exercised 8,190 shares at a strike of $2.07, covered exercise/tax liability with 4,289 shares and returned $317,288 worth of shares to the company (8,461 units at $37.50), closing all direct ownership in the company to cover taxes
- SEC Form 4: Zafirovski Mike S returned $4,604,062 worth of shares to the company (122,775 units at $37.50), closing all direct ownership in the company (withholding tax)
Latest DXCM
- Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program
- Executive Chair Sayer Kevin R sold $2,041,999 worth of shares (26,756 units at $76.32) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 328,970 units (SEC Form 4)
- EVP Chief Legal Compliance Off Brown Michael Jon sold $126,514 worth of shares (1,700 units at $74.42) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 104,653 units (SEC Form 4)
- Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes
- Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time
- Executive Chair Sayer Kevin R sold $1,926,432 worth of shares (26,756 units at $72.00) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 355,726 units (SEC Form 4)
- Dexcom Further Advances Vision of Glucose Biosensing for All
- Deutsche Bank initiated coverage on Dexcom with a new price target
- EVP Chief Legal Compliance Off Brown Michael Jon sold $128,435 worth of shares (1,700 units at $75.55) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 106,353 units (SEC Form 4)
- Director Foletta Mark G sold $296,540 worth of shares (4,000 units at $74.13) as part of a pre-agreed trading plan (SEC Form 4)